OKYO Pharma Ltd ADR (OKYO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has a cash flow conversion efficiency ratio of 0.448x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.53 Million) by net assets ($-3.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OKYO Pharma Ltd ADR - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how OKYO Pharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OKYO Pharma Ltd ADR (OKYO) total liabilities for a breakdown of total debt and financial obligations.
OKYO Pharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OKYO Pharma Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Susco Public Company Limited
BK:SUSCO
|
0.112x |
|
U-Tech Media Corp
TW:3050
|
0.033x |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
0.027x |
|
Kuangli Photoelectric Technology Co Ltd
TW:6431
|
-0.166x |
|
The Investment Trust Of India Limited
NSE:THEINVEST
|
-0.402x |
|
Ailleron S.A.
WAR:ALL
|
0.088x |
|
Choheung
KO:002600
|
0.149x |
|
Bali Bintang Sejahtera Tbk PT
JK:BOLA
|
-0.009x |
Annual Cash Flow Conversion Efficiency for OKYO Pharma Ltd ADR (2008–2025)
The table below shows the annual cash flow conversion efficiency of OKYO Pharma Ltd ADR from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see market value of OKYO Pharma Ltd ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-5.55 Million | $-1.81 Million | 0.326x | -79.78% |
| 2024-03-31 | $-5.88 Million | $-9.49 Million | 1.614x | -56.93% |
| 2023-03-31 | $-2.05 Million | $-7.70 Million | 3.748x | +302.02% |
| 2022-03-31 | $2.95 Million | $-5.47 Million | -1.855x | -516.71% |
| 2021-03-31 | $5.32 Million | $-1.60 Million | -0.301x | -103.50% |
| 2020-03-31 | $-139.80K | $-1.20 Million | 8.599x | +243.95% |
| 2019-03-31 | $333.14K | $-1.99 Million | -5.973x | -617.91% |
| 2018-03-31 | $1.92 Million | $-1.59 Million | -0.832x | -3413.06% |
| 2017-03-31 | $27.50 Million | $-651.27K | -0.024x | -16.45% |
| 2016-03-31 | $32.00 Million | $-650.88K | -0.020x | +51.37% |
| 2015-03-31 | $33.90 Million | $-1.42 Million | -0.042x | +43.12% |
| 2014-03-31 | $46.96 Million | $-3.45 Million | -0.074x | +13.40% |
| 2013-03-31 | $45.02 Million | $-3.82 Million | -0.085x | +24.82% |
| 2012-03-31 | $41.36 Million | $-4.67 Million | -0.113x | -38.07% |
| 2011-03-31 | $16.01 Million | $-1.31 Million | -0.082x | -403.21% |
| 2010-03-31 | $54.05 Million | $-878.61K | -0.016x | -174.19% |
| 2009-03-31 | $38.18 Million | $-226.35K | -0.006x | +68.33% |
| 2008-03-31 | $27.46 Million | $-513.95K | -0.019x | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more